Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Peptides

PT-141 10 mg

$85Per Unit

Synthetic cyclic heptapeptide analog of alpha-MSH targeting MC3 and MC4 receptors. Produced under stringent laboratory quality controls.

Lot PT1412026-07G · COA on request
Lyophilized peptide, sterile vial, 10 mg fill
2–8°C

5 × $85.00 = $425.00 $276.25 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

PT-141 10 mg

$276.25 for 5 · 35% off

Research use only
PT-141 10 mg research packaging
Lyophilized peptide, sterile vial, 10 mg fill
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot PT1412026-07G) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

PT-141 (bremelanotide)(Bremelanotide)

Regulatory status
FDA-approved medicine (Vyleesi, Jun 2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Strongest evidence
Approved drug backed by two phase 3 trials (effect sizes debated)
Overview

Bremelanotide is a synthetic peptide related to alpha-MSH that acts on melanocortin receptors in the brain.

What researchers study it for
  • Hypoactive sexual desire disorder in premenopausal women
Mechanism

Melanocortin receptor (mainly MC4R) agonist acting on central pathways involved in sexual desire.

Evidence (3)
  1. Human · randomized trial

    RECONNECT phase 3 trials (Obstet Gynecol 2019)

    1,267 premenopausal women in two trials. Desire scores rose and related distress fell versus placebo; nausea, flushing and headache were more common (10% or more).[1]

  2. Review

    Critical re-analysis (J Sex Res 2024)

    Argues the measured benefits were small and questions some outcome choices.[2]

  3. Approved drug

    FDA approval

    Vyleesi approved Jun 21, 2019 (Drugs@FDA).[3]

Limitations of the evidence
  • Approved for one indication in one population.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (3)
  1. 1.Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsKingsberg SA et al. Obstet Gynecol. 2019 Human · randomized trial
  2. 2.Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire DisorderSpielmans GI, Ellefson EM. J Sex Res. 2024 Review
  3. 3.Vyleesi (bremelanotide) - original approval 2019-06-21Drugs@FDA, NDA 210557 Approved drug
Every published studyPubMed search: bremelanotide OR PT-141(opens in a new tab)Every registered trialClinicalTrials.gov search: bremelanotide OR PT-141(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.